Business Wire

NV-1NCE

5.1.2023 15:31:41 CET | Business Wire | Press release

Share
1NCE expands IoT software business with launch of 1NCE OS

1NCE, a global IoT connectivity and software company, today announced the creation of its software business unit in conjunction with the Consumer Electronics Show launch of 1NCE OS – IoT software offering powerful developer tools and device control to make IoT even more accessible.

The software tools are an integral part of 1NCE’s Lifetime Flat service and are available complimentary to 1NCE customers.

1NCE OS is a foundational element of the company’s ambitious goal: to cement 1NCE’s standing as the preeminent destination for accessible IoT. It’s designed for easy integration of 1NCE’s connectivity and software features into IoT projects of any scale, for new and existing projects alike. Using 1NCE OS for device and cloud integration, customers can accelerate time-to-market for IoT projects by months. One of 1NCE’s core principles is that customer data isn’t to be monetized and used to sell additional services. Instead, 1NCE is transparent about turning data into tools that are included in the global lifetime flat rate.

Features available at launch:

  • Device Authentication: The process of setting up a secure and automated solution usually requires a complicated and error-prone onboarding process. 1NCE OS makes it simple: customers just solder the secure SIM into their device just like any other hardware piece and that’s it – delivering better authentication and integration of uniquely identified devices into IoT projects.
  • IoT Integrator: Reliably connecting devices to the cloud can be complex, but 1NCE’s managed protocol translation uses open industry standards (UDP, CoAP, LwM2M, AWS IoT Core, Webhooks) to give customers the free and full flexibility they demand.
  • Device Inspector: The time-intensive and costly process of sending technicians into the field to monitor and service devices is significantly reduced using advanced remote access to device states and recent telemetry.
  • Device Locator: Network based positioning helps users locate devices even without GPS.
  • Energy Saver: The inherent challenges of battery-powered devices make power usage a high priority, and 1NCE’s optimized payload transmission can increase battery life by up to 50 percent.

Fredrik Stålbrand of Berg Insights said: “1NCE OS and 1NCE’s product roadmap look very compelling. Our view is that the IoT connectivity market will increasingly move towards digitalized sales and delivery. SIMs will be pre-installed in chipsets, while connectivity management is increasingly being controlled by SaaS applications. Customers expect simple, digital experiences throughout the product lifecycle. 1NCE is clearly at the forefront of this development.”

Ivo Rook, Chief Operating Officer at 1NCE: “1NCE flips the script for customers – we don’t monetize their data for a few extra dollars because our customers’ data is theirs and theirs alone. 1NCE’s move into software allows us to boost our customers’ ideas not just when they need connectivity, but from the outset of their projects and all the way through a device’s lifecycle. IoT connectivity and software for life for a single fee, and that’s it.”

Fifty percent of failed IoT projects falter in the pilot stage. For new IoT projects, 1NCE makes it easy to experiment early without major expenditures that can kill a project. Customers connect sensors across the globe at a fraction of the cost of the traditional price of network operators, and now with 1NCE OS, they gain access to software tools that accelerate time-to-market without vendor lock-in or paying for unnecessary features packaged into most IoT platforms. And for IoT projects that are already up and running, 1NCE’s combination of connectivity and software delivers trusted, production-grade solutions for continuous improvement and optimization.

The majority of IoT projects require multinational deployments, but few network operators have the capability to truly meet cross-border demands. The 1NCE Lifetime Flat service is industry-disruptive but simple: for $10/€10, customers can deploy, connect, and manage IoT sensors across the world for as little as a dollar per year per device. More than 10,000 customers worldwide already trust 1NCE with more than 15 million managed connections.

The company’s ability to deliver affordable and reliable IoT, and its rapid global expansion to 153 markets from 106 at the beginning of the year, helped 1NCE earn two prestigious awards recently: Honorable Mention on Fast Company’s list of the Next Big Things in Tech and top prize for the most outstanding use case in “innovative IoT” (in partnership with Flashnet) at Light Reading’s 18th annual Leading Lights.

More information about 1NCE OS can be found here and customers can get started with 1NCE at the company’s online shop and the AWS Marketplace. Customer support is available in 14 languages.

About 1NCE

1NCE is the only connectivity and software company providing IoT at a lifetime global flat rate. Our mission is to deliver true cross-border, future-proof IoT without uncertainty or hassle over the lifetime of a device. In 150+ countries, 1NCE turns connectivity into electricity ready for consumption – opening the world of IoT to innovators who will dramatically improve the environment, cities, healthcare, public safety, the supply chain and more. The company, founded in 2017 by CEO Alexander P. Sator together with Deutsche Telekom AG, is headquartered in Cologne, Germany and has 250+ staff across 20 countries. Learn more online and follow 1NCE on Twitter, LinkedIn and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005461/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye